Respiratory Inhaler Devices Market: Digital Adherence Tracking Meets a Propellant Phase-Out

Between 2020 and 2025 the category grew near a 6.7% annual pace as respiratory disease diagnosis rates recovered steadily from pandemic-era care disruption, before smart connected inhaler adoption accelerated from 2023 onward as digital health reimbursement pathways expanded across major payer markets simultaneously. That recovery pattern held broadly steady across nearly every major prescribing market.
The base case carries the market to a 7.6% CAGR on three commercial mechanisms: smart inhaler adoption scaling as payers reward documented adherence data with preferred formulary placement, propellant phase-out mandates forcing manufacturers to reformulate and requalify metered-dose inhaler product lines across every major regulated market, and biologic delivery devices expanding as severe asthma and chronic obstructive pulmonary disease treatment protocols increasingly specify injectable and inhaled biologic combination therapy. No single mechanism alone would sustain this pace on its own.
The bull case at 8.8% assumes digital adherence reimbursement expands faster than currently modelled across major payer systems. The bear case at 6.4% assumes propellant reformulation costs and regulatory delays constrain product launch timelines more sharply than expected across the forecast period. Both scenarios hinge on how quickly payers and regulators act on emerging signals.